Mercury Computer Systems, Inc. (NASDAQ: MRCY) a trusted ISR subsystems
provider, announced that it will participate in the Sidoti & Company 15th
Annual Emerging Growth Conference to be held on March 23, 2011, at the
Grand Hyatt Hotel in New York City. Management will present an overview
... read more
Synergetics USA, Inc. (NASDAQ: SURG) announced that the Company will
participate in the Roth Capital Partners 23rd Annual OC
Growth Stock Conference on Wednesday, March 16, 2011, at
2:00 p.m. Pacific time. The Conference will be held at The Ritz Carlton
in Dana Point, California. Presenting on behalf of ... read more
With the iPad 2 shipping tomorrow, the RECOMMERCE industry has already seen its busiest week yet with tens of thousands looking to trade in to trade up. More iPads were traded in last week than any product in CE history. As a result, Gazelle, the nation's leading RECOMMERCE service predicts that not only will the iPad 2 be an excellent product for Apple, but it will also be a great upgrade with millions of original iPad owners likely to purchase ... read more
NeuMedia, Inc. (OTC Bulletin Board: MNDL), the leading provider of digital entertainment content and targeted internet advertising to mobile phone users, today announced that it has retained Hayden IR, a national, New York-based investor relations consulting firm, to develop and implement a strategic investor relations program to raise its visibility and strengthen its relationships with the investment community.
"The mobile internet advertising space is one of the fastest growing media segments, and it is rapidly becoming one of the most ... read more
Small Bone Innovations, Inc. (SBi), an orthopedics company focused
exclusively on serving patients and their physicians with technologies
and treatments for joint repair (arthroplasty) and trauma reconstruction
around the small bones & joints of the thumb, fingers, hand, wrist,
elbow, toes, and foot & ankle, reported ... read more
THE WOODLANDS, TX -- (Marketwire) -- 03/10/11 -- UniPixel, Inc. (NASDAQ: UNXL), a provider
of Clearly Superior Performance Engineered Films to the touch screen,
flexible electronics, lighting and display markets, reported its results
for the full year ended December 31, 2010.
2010 Operational Highlights
UniPixel sold its TMOS display technology to Rambus in May, and entered
into an engineering services agreement to help support Rambus' further
development of this technology in the lighting and display markets. The
sale ... read more
SAN DIEGO, CA -- (Marketwire) -- 03/10/11 -- Cytori Therapeutics (NASDAQ: CYTX) grew
product sales 41% and made substantial progress in advancing its
cardiovascular device product pipeline during 2010. An overview of the
Company's 2010 financial results is below and a review of its business
plans for 2011 is provided in the '2010 Results Shareholder Letter,' which
may be accessed at http://ir.cytoritx.com.
Key highlights for 2010 and through the beginning of 2011 include the
-- Grew product revenues 41% year-over-year. Revenue generating units
... read more
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced 2010 fourth quarter and full year financial results and accomplishments.
Optimer reported a net loss for the three months ended December 31, 2010 of $11.9 million, or $0.31 per common share, as compared to a net loss of $9.4 million, or $0.28 per common share, for the same period in 2009. Optimer reported a net loss for the year ended December 31, 2010 of $47.3 million, or $1.25 per common share, ... read more
FiberTower Corporation (Nasdaq: FTWR), a wireless backhaul services provider, reported results for the fourth quarter and year ended December 31, 2010.
Highlights for the Quarter
-- Service revenues net of early termination liability (ETL) grew 20% to
$20.1 million in the 2010 fourth quarter from $16.7 million in the 2009
-- Average monthly revenue per deployed site ... read more
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC). The data showed that adding aflibercept to the chemotherapy drug docetaxel did not meet the pre-specified criteria for the primary endpoint of improvement in overall survival compared with a regimen of docetaxel plus placebo (HR=1.01, CI: 0.868 to 1.174). The ... read more
Inc. (Nasdaq: PROJ) today announced that it is expanding its
reach to the Belgian and Luxemburg markets by opening a new office in
Deltek is the leading global provider of enterprise software and
... read more
Shuffle Master, Inc. (NASDAQ Global Select Market: SHFL) (“Shuffle
Master” or the “Company”) today announced its results for the first
quarter ended January 31, 2011.
"I am pleased with the performance in each of our product segments,
particularly our ... read more
Unify Corp. (NASDAQ: UNFY), an information management and eDiscovery
company, today announced financial results for its fiscal 2011 third
quarter, ended January 31, 2011.
Third Quarter Summary
... read more
Get content from Velux at:
Various shots from Ocean Sprint 3 of the Velux 5 Oceans around the world Yacht race. Includes aerial shots and at sea shot of all 4 competitors. Also includes the arrival of each skipper in Punta del Este and champagne celebration shots.
thenewsmarket.com delivers free broadcast- and streaming-quality video and multimedia content directly to media around the world, 24/7. More than 25,000 media outlets in 190+ countries use thenewsmarket.com, including the AP, BBC, CNBC, CNN, ... read more
BOTHELL, WA -- (Marketwire) -- 03/10/11 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer
of RNA-based drugs, today reported financial results for the three and 12
months ended December 31, 2010.
"Our key accomplishments in 2010 position AVI for significant progress this
year," said Chris Garabedian, president and chief executive officer of AVI
BioPharma. "These accomplishments include proof-of-concept data from our
clinical study of AVI-4658 in Duchenne muscular dystrophy patients and the
award of government contracts totaling more than $300 million for our
infectious disease programs. As ... read more
Omnicom Group Inc. (NYSE: OMC) and AOL Inc. (NYSE: AOL) have formed a partnership to infuse digital technology into the beginning of the creative process and enrich creative executions through a more cohesive use of technology in campaigns.
AOL will appoint an Omnicom Creative Ambassador, dedicated to bringing Omnicom creative agencies closer to AOL, as Omnicom works to build a stronger relationship between these agencies and media companies such as AOL.
"Wherever there is an opportunity to enhance campaigns through innovative products ... read more
Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced the completion of its rights offering and private placement that together resulted in gross proceeds of approximately $3.2 million to Nephros. The aggregate net proceeds received by Nephros from the rights offering and private placement are estimated to be approximately $2.3 million, after deducting the estimated aggregate expenses of these transactions, the repayment of ... read more
BOTHELL, WA and VANCOUVER, March 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals,
Inc. (NASDAQ: OGXI) today announced its fourth quarter and year end
2010 financial results, reviewed updates to the Company's development
programs and provided an outlook for 2011.
"Over the course of the last twelve months we've delivered on our
corporate objectives to initiate two Phase 3 clinical trials evaluating
custirsen in castrate-resistant prostate cancer and a randomized Phase
2 clinical trial evaluating OGX-427 in chemo-therapy naïve advanced
prostate cancer, creating a ... read more
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2010.
Three months ended December 31, 2010
For the three months ended December 31, 2010, Orexigen reported a net loss of $11.3 million, or $0.24 per share, as compared to a net loss of $15.0 million, or $0.32 per share, for the fourth quarter of 2009. As of December 31, 2010, Orexigen had $24.9 ... read more